Skip to main content
Premium Trial:

Request an Annual Quote

APBiotech Licenses GFP Technology from Aurora Biosciences

NEW YORK, Sept. 10 – Amersham Pharmacia Biotech has licensed green fluorescent protein technology from Aurora Biosciences, the company announced Monday.

The license gives APBiotech worldwide exclusive rights to the technology, said Kevin McCormack, marketing director for lead screening systems at APBiotech.

The company would not disclose the length of the licensing agreement or financial details of the agreement.

GFP technology aids researchers in identifying cellular expressions of a gene by enabling fluorescent detection of the phenotype. Applications of the technology include functional genomics, high-throughput screening assays, and gene profiling to assess the potential toxicity of compounds.

McCormack said the Aurora license would augment the GFP technology APBiotech already licenses from Denmark-based BioImage, giving customers one-stop access to GFP technology.

“In order to utilize GFP, you need a specific set of mutations, a very complex web of IP,” said McCormack. “Pooling IP from Aurora and BioImage gives a complete portfolio of IP for our customers.”

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.